Physician profile
Karl E Studtmann
NPI 1477545283
$3,014.68
in general payments reported to CMS, 2019-2025
13 companies · $123 in 2025
The $123 reported for 2025 was less than what a typical Otolaryngology provider received nationally (typical 2025 total: $317).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,607 · 2020: $261 · 2021: $85.10 · 2022: $169 · 2023: $455 · 2024: $314 · 2025: $123.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $892.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $892.19 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Stryker Corporation | $1,773.48 | 2019-2021 | |
| Glaxosmithkline, LLC. | $343.88 | 2022-2024 | Nucala |
| Inspire Medical Systems, INC. | $308.62 | 2023-2025 | Inspire |
| Aerin Medical INC. | $151.39 | 2021-2024 | |
| Integra Lifesciences Corporation | $136.56 | 2023 | Microfrance, Codman Isocool Aht, Instruments-Orthopedic |
| Optinose US, INC. | $73.01 | 2021-2022 | |
| Medtronic, INC. | $63.06 | 2023 | Stealthstation S8 Platform |
| Alk-Abello, INC | $62.52 | 2019-2020 | |
| Smith+Nephew, INC. | $24.68 | 2024 | Tula |
| Intersect Ent, INC. | $22.46 | 2020 | |
| Genzyme Corporation | $20.67 | 2019 | |
| Olympus America INC. | $18.56 | 2019 | |
| Novartis Pharmaceuticals Corporation | $15.79 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Karl Studtmann listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.